Rapport Therapeutics公司在2026年美国神经病学学会年会上公布了其候选药物Rap-219针对局灶性发作癫痫的2a期临床试验随访期数据。研究结果显示，该药物在延长观察期内持续表现出显著的癫痫发作减少效果。
此次公布的随访数据进一步验证了Rap-219在控制癫痫发作方面的持久疗效。临床试验参与者经过长期用药后，癫痫发作频率保持稳定下降趋势，这一发现为药物的长期安全性和有效性提供了重要证据。
研究人员指出，持续性的癫痫控制效果对于改善患者生活质量具有重要意义。Rap-219在随访期间展现出的良好耐受性特征，也为后续更大规模的临床研究奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.